January 3rd 2024
This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.
REGENXBIO announces second pivotal trial, ASCENT, in RGX-314 clinical program
January 18th 2022ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.
LIGHTSITE II: Photobiomodulation a novel therapy for dry AMD
September 12th 2021During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.
Wet AMD treatment burden eased by nonviral gene therapy
May 3rd 2021EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.